Tabrecta สหภาพยุโรป - ลัตเวีย - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Rosulip 40 mg/10 mg cietās kapsulas ลัตเวีย - ลัตเวีย - Zāļu valsts aģentūra

rosulip 40 mg/10 mg cietās kapsulas

egis pharmaceuticals plc, hungary - rosuvastatinum, ezetimibum - kapsula, cietā - 40 mg/10 mg

Rosulip 20 mg/10 mg cietās kapsulas ลัตเวีย - ลัตเวีย - Zāļu valsts aģentūra

rosulip 20 mg/10 mg cietās kapsulas

egis pharmaceuticals plc, hungary - rosuvastatinum, ezetimibum - kapsula, cietā - 20 mg/10 mg